GolDBeaR personal page - To The Moon

GolDBeaR

GolDBeaR

No personal profile

12Follow

5Followers

0Topic

0Badge

02-06

$Palantir Technologies Inc.(PLTR)$

2022-08-03

$Moderna, Inc.(MRNA)$keep up

2022-07-14

Come on

Sorry, the original content has been removed

2022-07-14

$Palantir Technologies Inc.(PLTR)$ waiting for

2022-01-04

Covid last forever

Sorry, the original content has been removed

2022-01-04

Superb

Tesla Adds $144 Billion to Market Value After Record Deliveries

2021-12-31

Superb

2021-12-27

Sounds sweet

Sorry, the original content has been removed

2021-12-27

Up up

@4ZOEYS:$Tiger Brokers(TIGR)$Moved a little too fast,

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4095642275585470","uuid":"4095642275585470","gmtCreate":1635384032915,"gmtModify":1641713927280,"name":"GolDBeaR","pinyin":"goldbear","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":12,"tweetSize":33,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.07.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":271133400080600,"gmtCreate":1707232627986,"gmtModify":1707232631259,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","text":"$Palantir Technologies Inc.(PLTR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271133400080600","isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9906656398,"gmtCreate":1659538651317,"gmtModify":1705981390546,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","listText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","text":"$Moderna, Inc.(MRNA)$keep up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906656398","isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076167786,"gmtCreate":1657812205945,"gmtModify":1676536065700,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Come on","listText":"Come on","text":"Come on","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076167786","repostId":"1178687942","repostType":2,"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076165077,"gmtCreate":1657811900999,"gmtModify":1676536065661,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$ waiting for","images":[{"img":"https://community-static.tradeup.com/news/d673b361e8e98bbbaccd32998ce2b23b","width":"1344","height":"2389"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076165077","isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9001793279,"gmtCreate":1641311984824,"gmtModify":1676533596753,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Covid last forever","listText":"Covid last forever","text":"Covid last forever","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001793279","repostId":"1143463942","repostType":2,"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001559759,"gmtCreate":1641283730205,"gmtModify":1676533592864,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001559759","repostId":"1102940638","repostType":2,"repost":{"id":"1102940638","pubTimestamp":1641254417,"share":"https://ttm.financial/m/news/1102940638?lang=&edition=fundamental","pubTime":"2022-01-04 08:00","market":"us","language":"en","title":"Tesla Adds $144 Billion to Market Value After Record Deliveries","url":"https://stock-news.laohu8.com/highlight/detail?id=1102940638","media":"Bloomberg","summary":"Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worl","content":"<html><head></head><body><ul><li>Monday’s 14% gain is stock’s best performance to start a year</li><li>Company delivered 308,600 vehicles worldwide in fourth quarter</li></ul><p>Tesla Inc. is off to a strong start to the new year after the electric-car maker smashed its quarterly record for deliveries in what one analyst called a “trophy-case” performance.</p><p>The company’s shares jumped 14% in New York, their biggest gain since March and best start to a year since Tesla went public more than a decade ago. The $144 billion in market value that Tesla added on Monday is the equivalent of an entire Honeywell International Inc. or Starbucks Corp. It’s also more than the value of almost 90% of the companies in the S&amp;P 500 Index.</p><p><img src=\"https://static.tigerbbs.com/b98c9fe43c27a22e44f07c72304c2671\" tg-width=\"1200\" tg-height=\"675\" referrerpolicy=\"no-referrer\"/></p><p>Worldwide deliveries totaled 308,600 vehicles in the fourth quarter, well ahead of the average analyst estimate of roughly 263,000 vehicles, and topping the company’s previous record of 241,300 from the prior quarter. Annual handovers surged to more than 936,000 in 2021, up 87% from the previous year’s level, Austin, Texas-based Tesla said Sunday.</p><p>“This is a trophy-case quarter for Tesla as the company blew away even bull-case expectations,” Daniel Ives, an analyst at Wedbush Securities, said in an email. He called it a “jaw-dropper performance” for the end of the year that gives “massive tailwinds” heading into 2022.</p><p>The record quarter underscores the “green tidal wave taking hold” for Tesla and Chief Executive Officer Elon Musk, Ives said in a note to clients. The results also point to robust demand in China and Tesla’s skill at navigating the global semiconductor shortage, he said.</p><p>Musk, who has pledged delivery growth despite the “supply-chain nightmare” of 2021, praised his crew on Twitter.</p><p><img src=\"https://static.tigerbbs.com/ee8ecf3d5f76e1a511459de02365693c\" tg-width=\"830\" tg-height=\"496\" referrerpolicy=\"no-referrer\"/></p><p>Quarterly deliveries are one of the most closely watched indicators for Tesla. They underpin its financial results and are widely seen as a barometer of consumer demand for electric vehicles as a whole because the company has led the charge for battery-powered cars.</p><p>Tesla has said repeatedly it expects 50% annual increases in deliveries over a multiyear period. The seventh consecutive quarterly gain comes amid a global semiconductor slump that has crimped production at most other automakers and kept sales in check despite rising demand.</p><p>“Tesla continues to execute well, posting deliveries and production above consensus expectations,” Cowen analyst Jeffrey Osborne said. “As the competition heats up from incumbent OEMs and new entrants alike, we see 2022 becoming a critical year for Tesla.”</p><p>The EV market leader’s stock soared almost 50% in 2021 to give it a market valuation exceeding $1 trillion -- one of only a handful of U.S.-based public companies to achieve that status.</p><p>The shares reached a record high in early November before plunging after Musk began unloading 10% of his stake.</p><p><a href=\"https://ttm.financial/NW/1195533166\" target=\"_blank\"><b>Elon Musk’s Fortune Climbs $30 Billion on Tesla’s Record Quarter for Deliveries</b></a><b></b></p><p>Elon Musk started 2022 with a bang.</p><p><img src=\"https://static.tigerbbs.com/9bb18462e67b743b94632bf0093ff927\" tg-width=\"1000\" tg-height=\"667\" referrerpolicy=\"no-referrer\"/></p><p>Tesla Inc. reported it had smashed its previous record for vehicle deliveries, spurring a rally in the electric car-maker’s shares and creating one of the biggest one-day jumps in wealth.</p><p>Musk’s fortune jumped by $33.8 billion on Monday to $304.2 billion, according to the Bloomberg Billionaires Index. Jeff Bezos, second on the list, has a $196 billion fortune.</p><p>Tesla’s shares rose 13.5% to $1,199.78 on Monday after fourth-quarter results handily exceeded analysts’ estimates for auto deliveries.</p><p>The company’s market valuation jumped back above $1 trillion last month after a dip in November and early December.</p><p>Musk, who owns about 18% of Tesla, helped trigger the slide when he said he would reduce his stake in the company by 10%. He’ssoldmore than $10 billion worth of shares since November, part of a plan to generate cash to pay tax obligations.</p><p>Musk’s net worth, which also includes his stake in rocket manufacterer SpaceX, reached a high of $340 billion last year, surpassing the peak inflation-adjusted net worth of John D. Rockefeller and briefly making him the richest person in modern history.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Adds $144 Billion to Market Value After Record Deliveries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Adds $144 Billion to Market Value After Record Deliveries\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-04 08:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worldwide in fourth quarterTesla Inc. is off to a strong start to the new year after the electric-car ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-03/tesla-set-for-record-start-to-new-year-after-blowout-deliveries","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102940638","content_text":"Monday’s 14% gain is stock’s best performance to start a yearCompany delivered 308,600 vehicles worldwide in fourth quarterTesla Inc. is off to a strong start to the new year after the electric-car maker smashed its quarterly record for deliveries in what one analyst called a “trophy-case” performance.The company’s shares jumped 14% in New York, their biggest gain since March and best start to a year since Tesla went public more than a decade ago. The $144 billion in market value that Tesla added on Monday is the equivalent of an entire Honeywell International Inc. or Starbucks Corp. It’s also more than the value of almost 90% of the companies in the S&P 500 Index.Worldwide deliveries totaled 308,600 vehicles in the fourth quarter, well ahead of the average analyst estimate of roughly 263,000 vehicles, and topping the company’s previous record of 241,300 from the prior quarter. Annual handovers surged to more than 936,000 in 2021, up 87% from the previous year’s level, Austin, Texas-based Tesla said Sunday.“This is a trophy-case quarter for Tesla as the company blew away even bull-case expectations,” Daniel Ives, an analyst at Wedbush Securities, said in an email. He called it a “jaw-dropper performance” for the end of the year that gives “massive tailwinds” heading into 2022.The record quarter underscores the “green tidal wave taking hold” for Tesla and Chief Executive Officer Elon Musk, Ives said in a note to clients. The results also point to robust demand in China and Tesla’s skill at navigating the global semiconductor shortage, he said.Musk, who has pledged delivery growth despite the “supply-chain nightmare” of 2021, praised his crew on Twitter.Quarterly deliveries are one of the most closely watched indicators for Tesla. They underpin its financial results and are widely seen as a barometer of consumer demand for electric vehicles as a whole because the company has led the charge for battery-powered cars.Tesla has said repeatedly it expects 50% annual increases in deliveries over a multiyear period. The seventh consecutive quarterly gain comes amid a global semiconductor slump that has crimped production at most other automakers and kept sales in check despite rising demand.“Tesla continues to execute well, posting deliveries and production above consensus expectations,” Cowen analyst Jeffrey Osborne said. “As the competition heats up from incumbent OEMs and new entrants alike, we see 2022 becoming a critical year for Tesla.”The EV market leader’s stock soared almost 50% in 2021 to give it a market valuation exceeding $1 trillion -- one of only a handful of U.S.-based public companies to achieve that status.The shares reached a record high in early November before plunging after Musk began unloading 10% of his stake.Elon Musk’s Fortune Climbs $30 Billion on Tesla’s Record Quarter for DeliveriesElon Musk started 2022 with a bang.Tesla Inc. reported it had smashed its previous record for vehicle deliveries, spurring a rally in the electric car-maker’s shares and creating one of the biggest one-day jumps in wealth.Musk’s fortune jumped by $33.8 billion on Monday to $304.2 billion, according to the Bloomberg Billionaires Index. Jeff Bezos, second on the list, has a $196 billion fortune.Tesla’s shares rose 13.5% to $1,199.78 on Monday after fourth-quarter results handily exceeded analysts’ estimates for auto deliveries.The company’s market valuation jumped back above $1 trillion last month after a dip in November and early December.Musk, who owns about 18% of Tesla, helped trigger the slide when he said he would reduce his stake in the company by 10%. He’ssoldmore than $10 billion worth of shares since November, part of a plan to generate cash to pay tax obligations.Musk’s net worth, which also includes his stake in rocket manufacterer SpaceX, reached a high of $340 billion last year, surpassing the peak inflation-adjusted net worth of John D. Rockefeller and briefly making him the richest person in modern history.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003327935,"gmtCreate":1640884649383,"gmtModify":1676533551118,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[{"img":"https://static.itradeup.com/news/04bd5d6fab6a75ca6b03b059bbdf6566","width":"1344","height":"2139"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003327935","isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9009825780,"gmtCreate":1640617239238,"gmtModify":1676533529571,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Sounds sweet","listText":"Sounds sweet","text":"Sounds sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009825780","repostId":"1114062676","repostType":2,"isVote":1,"tweetType":1,"viewCount":96,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9009823704,"gmtCreate":1640616470570,"gmtModify":1676533529449,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4095642275585470","authorIdStr":"4095642275585470"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009823704","repostId":"9009820967","repostType":1,"repost":{"id":9009820967,"gmtCreate":1640616177720,"gmtModify":1676533529377,"author":{"id":"3576159031156193","authorId":"3576159031156193","name":"4ZOEYS","avatar":"https://static.tigerbbs.com/485a6405c364ce85c22e81b2913d390f","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3576159031156193","authorIdStr":"3576159031156193"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","text":"$Tiger Brokers(TIGR)$Moved a little too fast,","images":[{"img":"https://static.itradeup.com/news/c56f3695dae52d48a6c8a24c1ca8e88d","width":"1125","height":"3766"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009820967","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9009825780,"gmtCreate":1640617239238,"gmtModify":1676533529571,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Sounds sweet","listText":"Sounds sweet","text":"Sounds sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009825780","repostId":"1114062676","repostType":2,"repost":{"id":"1114062676","pubTimestamp":1640603150,"share":"https://ttm.financial/m/news/1114062676?lang=&edition=fundamental","pubTime":"2021-12-27 19:05","market":"us","language":"en","title":"Got $1,000? 5 Stocks to Buy to Start 2022 With a Bang","url":"https://stock-news.laohu8.com/highlight/detail?id=1114062676","media":"Motley Fool","summary":"Growth, value, and income investors can still find incredible bargains in this market.","content":"<p>We've hit the homestretch. In just a few days we'll be turning the page on 2021 and looking toward a new, and hopefully less pandemic-disrupted year.</p>\n<p>Despite the challenges Wall Street has endured this year, the benchmark&nbsp;<b>S&amp;P 500</b>&nbsp;ended last week on a high note...<i>literally</i>. It was the 68th record-closing high for the widely followed index in 2021, which is the second-highest figure for all-time closing highs in a single year.</p>\n<p>And yet, bargains still remain for patient investors. If you have $1,000 ready to invest, which won't be needed to pay bills or cover emergencies, the following five stocks can help you start 2022 with a bang.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fb44d0c383bf1255feef321479451cf8\" tg-width=\"2000\" tg-height=\"1333\" referrerpolicy=\"no-referrer\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>CrowdStrike Holdings</b></p>\n<p>One of the best ways to put money to work in the stock market over the long run is to buy best-of-breed companies. Within the&nbsp;cybersecurity space, there's no company firing on all cylinders quite like&nbsp;<b>CrowdStrike Holdings</b>(NASDAQ:CRWD).</p>\n<p>The not-so-subtle secret to CrowdStrike's success is the company's cloud-native platform known as Falcon. Since it was built in the cloud and relies on artificial intelligence to grow smarter and more efficient at detecting and responding to threats over time, Falcon can actually be a more cost-efficient solution over the long run, even though it initially costs more than its competitors. CrowdStrike notes that Falcon oversees about 1 trillion events each day.</p>\n<p>CrowdStrike's ramp up&nbsp;has been nothing short of incredible. In under five years we've seen the company's subscriber base balloon from 450 to nearly 14,700. Additionally, the number of clients with four or more cloud-module subscriptions has catapulted from less than 10% to 68% over the same stretch. Because margins are so high with cybersecurity service subscriptions, CrowdStrike has been blowing the door off Wall Street's growth expectations, yet it's already achieved its long-term gross margin target of 77% to 82%+.</p>\n<p>Cybersecurity is arguably the safest fast-growing trend of the decade, making CrowdStrike the type of company that could make a splash in your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/74173fae42470420d52dba62b667f224\" tg-width=\"2000\" tg-height=\"1333\" referrerpolicy=\"no-referrer\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Annaly Capital Management</b></p>\n<p>In a market that only seems to care about&nbsp;growth stocks, one way investors can begin 2022 with a bang is by scooping up a cheap (trading below book value)&nbsp;ultra-high-yield dividend stock&nbsp;that can put inflation in its place. Say hello to&nbsp;<b>Annaly Capital Management</b>(NYSE:NLY)&nbsp;and its 10.7% dividend yield.</p>\n<p>Annaly Capital is a mortgage real estate investment trust (REIT). This might sound complicated, but the operating model is pretty straightforward. Annaly aims to borrow money at lower short-term rates, and uses this capital to acquire higher-yielding long-term assets, such as mortgage-backed securities (MBS). The goal is to maximize the gap between the average yield from MBSs minus the average borrowing rate, which is known as net interest margin.</p>\n<p>Annaly has two things working in its favor. First, it&nbsp;almost exclusively buys agency assets. These are securities backed by the federal government in the event of default. Though this added protection often means lower yields for the MBSs it buys, it also allows the company to safely utilize leverage to its advantage.</p>\n<p>Second, Annaly is in the sweet spot of its growth cycle. The early stages of an economic recovery usually features a steepening Treasury bond yield curve. As the gap between short-term and long-term T-bonds increases, so does Annaly's net interest margin.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2f8f7346de5067274f2c2bb3e94f9e5\" tg-width=\"2000\" tg-height=\"1335\" referrerpolicy=\"no-referrer\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>JD.com</b></p>\n<p>Few things have given investors more indigestion in 2021 than China stocks. But among the volatility sits one high-growth name investors can trust: online retailer&nbsp;<b>JD.com</b>(NASDAQ:JD).</p>\n<p>There are two ways that online marketplaces usually operate. The first model involves operating a third-party seller. An example would&nbsp;<b>Alibaba</b>&nbsp;allowing sellers to use its platform to move goods. The second method, which is deployed by JD.com, is to control the inventory and logistics while relying only minimally on third-party marketplaces. </p>\n<p>As of the end of September, JD had more than 552 million annual active customers shopping on its marketplace, which was up almost 111 million customers from the previous rolling 12-month stretch.&nbsp; Keep in mind that China's gross domestic product growth rate consistently outpaces most developed countries. This makes e-commerce a particularly intriguing opportunity in China.</p>\n<p>Additionally, don't overlook&nbsp;JD's push into new verticals, such as cloud services, advertising, and healthcare. Although these verticals represent a small portion of net sales, services grew by 43% in Q3 2021 from the previous year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/fac4401106e9e2a88e9a38658c2fcd10\" tg-width=\"2000\" tg-height=\"1333\" referrerpolicy=\"no-referrer\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Walgreens Boots Alliance</b></p>\n<p>Another value and income stock that would be perfect for long-term investors to buy with $1,000 is pharmacy chain&nbsp;<b>Walgreens Boots Alliance</b>(NASDAQ:WBA).</p>\n<p>Healthcare stocks&nbsp;are normally (pardon the pun) immune to the ebbs and flows of the stock market and U.S. economy. No matter how good or bad things are, people always need drugs, devices, and healthcare services. But foot-traffic dependent pharmacy chains like Walgreens were punched in the gut by the pandemic. The good news is you can now scoop up shares at near bargain-basement levels.</p>\n<p>Walgreens Boots Alliance is the midst of a&nbsp;multipoint turnaround strategyaimed at boosting margins and lifting its organic growth potential. The company has already achieved more than $2 billion in annual cost cuts a full year ahead of schedule, and it's investing heavily in digitization. Though brick-and-mortar pharmacy chains remain reliant on foot traffic, investing in direct-to-consumer sales is an easy way to lift sales.</p>\n<p>The company has also partnered with (and invested in) VillageMD to&nbsp;open co-located health clinics. What differentiates the Walgreens/VillageMD clinics from competitors is that they'll be physician-staffed and full service. These clinics shouldn't have any trouble attracting repeat patients that can be funneled directly to Walgreens' higher-margin pharmacy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f67080bb4dbe247432cd36d0e19766c9\" tg-width=\"2000\" tg-height=\"1333\" referrerpolicy=\"no-referrer\"><span>IMAGE SOURCE: META PLATFORMS.</span></p>\n<p><b>Meta Platforms</b></p>\n<p>A fifth and final stock that you can buy with $1,000 to start 2022 off with a bang is&nbsp;<b>Meta Platforms</b>(NASDAQ:FB), the parent company of social media giant Facebook.</p>\n<p>Although Meta may have changed its name two months ago, make no mistake that the vast majority of the company's revenue still originates from advertising on Facebook. When the September quarter ended, Facebook had 2.91 billion monthly active users (MAUs) visiting its site, with another 670 million unique MAUs heading to Instagram and/or WhatsApp.&nbsp; This combined&nbsp;3.58 billion MAUs&nbsp;represents more than half of the global adult population. It's no wonder Meta's ad-pricing power is higher than just about any company on the planet.</p>\n<p>As I've previously noted, Meta hasn't even depressed the gas pedal all the way, either. It'll generate more than $100 billion in ad revenue in 2021, yet almost all of this will come from Facebook and Instagram. If and when the company decides to meaningfully monetize Facebook Messenger and WhatsApp, we should see another sizable bump in sales, profits, and cash flow.</p>\n<p>Meta is also the premier play on the metaverse -- i.e., the next iteration of the internet that allows people to interact in 3D virtual environments. While significantly monetizing the metaverse remains a ways off, Meta Platforms&nbsp;has a front row seat&nbsp;for when that does occur.</p>\n<p>Meta may we be the best overall value among the&nbsp;FAANG stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? 5 Stocks to Buy to Start 2022 With a Bang</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? 5 Stocks to Buy to Start 2022 With a Bang\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-27 19:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/27/got-1000-5-stocks-to-buy-to-start-2022-with-a-bang/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We've hit the homestretch. In just a few days we'll be turning the page on 2021 and looking toward a new, and hopefully less pandemic-disrupted year.\nDespite the challenges Wall Street has endured ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/27/got-1000-5-stocks-to-buy-to-start-2022-with-a-bang/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JD":"京东","WBA":"沃尔格林联合博姿","CRWD":"CrowdStrike Holdings, Inc.","NLY":"Annaly Capital Management"},"source_url":"https://www.fool.com/investing/2021/12/27/got-1000-5-stocks-to-buy-to-start-2022-with-a-bang/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114062676","content_text":"We've hit the homestretch. In just a few days we'll be turning the page on 2021 and looking toward a new, and hopefully less pandemic-disrupted year.\nDespite the challenges Wall Street has endured this year, the benchmark S&P 500 ended last week on a high note...literally. It was the 68th record-closing high for the widely followed index in 2021, which is the second-highest figure for all-time closing highs in a single year.\nAnd yet, bargains still remain for patient investors. If you have $1,000 ready to invest, which won't be needed to pay bills or cover emergencies, the following five stocks can help you start 2022 with a bang.\nIMAGE SOURCE: GETTY IMAGES.\nCrowdStrike Holdings\nOne of the best ways to put money to work in the stock market over the long run is to buy best-of-breed companies. Within the cybersecurity space, there's no company firing on all cylinders quite like CrowdStrike Holdings(NASDAQ:CRWD).\nThe not-so-subtle secret to CrowdStrike's success is the company's cloud-native platform known as Falcon. Since it was built in the cloud and relies on artificial intelligence to grow smarter and more efficient at detecting and responding to threats over time, Falcon can actually be a more cost-efficient solution over the long run, even though it initially costs more than its competitors. CrowdStrike notes that Falcon oversees about 1 trillion events each day.\nCrowdStrike's ramp up has been nothing short of incredible. In under five years we've seen the company's subscriber base balloon from 450 to nearly 14,700. Additionally, the number of clients with four or more cloud-module subscriptions has catapulted from less than 10% to 68% over the same stretch. Because margins are so high with cybersecurity service subscriptions, CrowdStrike has been blowing the door off Wall Street's growth expectations, yet it's already achieved its long-term gross margin target of 77% to 82%+.\nCybersecurity is arguably the safest fast-growing trend of the decade, making CrowdStrike the type of company that could make a splash in your portfolio.\nIMAGE SOURCE: GETTY IMAGES.\nAnnaly Capital Management\nIn a market that only seems to care about growth stocks, one way investors can begin 2022 with a bang is by scooping up a cheap (trading below book value) ultra-high-yield dividend stock that can put inflation in its place. Say hello to Annaly Capital Management(NYSE:NLY) and its 10.7% dividend yield.\nAnnaly Capital is a mortgage real estate investment trust (REIT). This might sound complicated, but the operating model is pretty straightforward. Annaly aims to borrow money at lower short-term rates, and uses this capital to acquire higher-yielding long-term assets, such as mortgage-backed securities (MBS). The goal is to maximize the gap between the average yield from MBSs minus the average borrowing rate, which is known as net interest margin.\nAnnaly has two things working in its favor. First, it almost exclusively buys agency assets. These are securities backed by the federal government in the event of default. Though this added protection often means lower yields for the MBSs it buys, it also allows the company to safely utilize leverage to its advantage.\nSecond, Annaly is in the sweet spot of its growth cycle. The early stages of an economic recovery usually features a steepening Treasury bond yield curve. As the gap between short-term and long-term T-bonds increases, so does Annaly's net interest margin.\nIMAGE SOURCE: GETTY IMAGES.\nJD.com\nFew things have given investors more indigestion in 2021 than China stocks. But among the volatility sits one high-growth name investors can trust: online retailer JD.com(NASDAQ:JD).\nThere are two ways that online marketplaces usually operate. The first model involves operating a third-party seller. An example would Alibaba allowing sellers to use its platform to move goods. The second method, which is deployed by JD.com, is to control the inventory and logistics while relying only minimally on third-party marketplaces. \nAs of the end of September, JD had more than 552 million annual active customers shopping on its marketplace, which was up almost 111 million customers from the previous rolling 12-month stretch.  Keep in mind that China's gross domestic product growth rate consistently outpaces most developed countries. This makes e-commerce a particularly intriguing opportunity in China.\nAdditionally, don't overlook JD's push into new verticals, such as cloud services, advertising, and healthcare. Although these verticals represent a small portion of net sales, services grew by 43% in Q3 2021 from the previous year.\nIMAGE SOURCE: GETTY IMAGES.\nWalgreens Boots Alliance\nAnother value and income stock that would be perfect for long-term investors to buy with $1,000 is pharmacy chain Walgreens Boots Alliance(NASDAQ:WBA).\nHealthcare stocks are normally (pardon the pun) immune to the ebbs and flows of the stock market and U.S. economy. No matter how good or bad things are, people always need drugs, devices, and healthcare services. But foot-traffic dependent pharmacy chains like Walgreens were punched in the gut by the pandemic. The good news is you can now scoop up shares at near bargain-basement levels.\nWalgreens Boots Alliance is the midst of a multipoint turnaround strategyaimed at boosting margins and lifting its organic growth potential. The company has already achieved more than $2 billion in annual cost cuts a full year ahead of schedule, and it's investing heavily in digitization. Though brick-and-mortar pharmacy chains remain reliant on foot traffic, investing in direct-to-consumer sales is an easy way to lift sales.\nThe company has also partnered with (and invested in) VillageMD to open co-located health clinics. What differentiates the Walgreens/VillageMD clinics from competitors is that they'll be physician-staffed and full service. These clinics shouldn't have any trouble attracting repeat patients that can be funneled directly to Walgreens' higher-margin pharmacy.\nIMAGE SOURCE: META PLATFORMS.\nMeta Platforms\nA fifth and final stock that you can buy with $1,000 to start 2022 off with a bang is Meta Platforms(NASDAQ:FB), the parent company of social media giant Facebook.\nAlthough Meta may have changed its name two months ago, make no mistake that the vast majority of the company's revenue still originates from advertising on Facebook. When the September quarter ended, Facebook had 2.91 billion monthly active users (MAUs) visiting its site, with another 670 million unique MAUs heading to Instagram and/or WhatsApp.  This combined 3.58 billion MAUs represents more than half of the global adult population. It's no wonder Meta's ad-pricing power is higher than just about any company on the planet.\nAs I've previously noted, Meta hasn't even depressed the gas pedal all the way, either. It'll generate more than $100 billion in ad revenue in 2021, yet almost all of this will come from Facebook and Instagram. If and when the company decides to meaningfully monetize Facebook Messenger and WhatsApp, we should see another sizable bump in sales, profits, and cash flow.\nMeta is also the premier play on the metaverse -- i.e., the next iteration of the internet that allows people to interact in 3D virtual environments. While significantly monetizing the metaverse remains a ways off, Meta Platforms has a front row seat for when that does occur.\nMeta may we be the best overall value among the FAANG stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":96,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076167786,"gmtCreate":1657812205945,"gmtModify":1676536065700,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Come on","listText":"Come on","text":"Come on","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076167786","repostId":"1178687942","repostType":2,"repost":{"id":"1178687942","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1657807271,"share":"https://ttm.financial/m/news/1178687942?lang=&edition=fundamental","pubTime":"2022-07-14 22:01","market":"us","language":"en","title":"EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178687942","media":"Tiger Newspress","summary":"EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.","content":"<html><head></head><body><p>EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.<img src=\"https://static.tigerbbs.com/e4346325d5520a81cba5e77d0588bce5\" tg-width=\"265\" tg-height=\"357\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks Dipped in Morning Trading, With Rivian Sliding Over 3% and Tesla Sliding Over 2%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-07-14 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.<img src=\"https://static.tigerbbs.com/e4346325d5520a81cba5e77d0588bce5\" tg-width=\"265\" tg-height=\"357\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc.","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178687942","content_text":"EV stocks dipped in morning trading, with Rivian sliding over 3% and Tesla sliding over 2%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001559759,"gmtCreate":1641283730205,"gmtModify":1676533592864,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001559759","repostId":"1102940638","repostType":2,"isVote":1,"tweetType":1,"viewCount":378,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":271133400080600,"gmtCreate":1707232627986,"gmtModify":1707232631259,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$&nbsp;</a>","text":"$Palantir Technologies Inc.(PLTR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271133400080600","isVote":1,"tweetType":1,"viewCount":145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9906656398,"gmtCreate":1659538651317,"gmtModify":1705981390546,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","listText":"<a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$</a>keep up","text":"$Moderna, Inc.(MRNA)$keep up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906656398","isVote":1,"tweetType":1,"viewCount":243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9076165077,"gmtCreate":1657811900999,"gmtModify":1676536065661,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","listText":"<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a> waiting for&nbsp;","text":"$Palantir Technologies Inc.(PLTR)$ waiting for","images":[{"img":"https://community-static.tradeup.com/news/d673b361e8e98bbbaccd32998ce2b23b","width":"1344","height":"2389"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9076165077","isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9001793279,"gmtCreate":1641311984824,"gmtModify":1676533596753,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Covid last forever","listText":"Covid last forever","text":"Covid last forever","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001793279","repostId":"1143463942","repostType":2,"repost":{"id":"1143463942","pubTimestamp":1640831989,"share":"https://ttm.financial/m/news/1143463942?lang=&edition=fundamental","pubTime":"2021-12-30 10:39","market":"us","language":"en","title":"Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=1143463942","media":"WSJ","summary":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with ","content":"<html><head></head><body><p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.</p><p>The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.</p><p>At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?</p><p>Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.</p><p>“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/391659260599217c12076cea6c888697\" tg-width=\"1007\" tg-height=\"668\" width=\"100%\" height=\"auto\"/><span>The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNAL</span></p><p>The emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.</p><p>Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.</p><p>They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly&amp; Co.’s cancer drug Alimta, based on research by a university professor.</p><p>Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.</p><p>Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/125cd1b51bc213c732cc20b023d56df3\" tg-width=\"1352\" tg-height=\"734\" width=\"100%\" height=\"auto\"/><span>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESS</span></p><p>The market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.</p><p>Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.</p><p>Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.</p><p>One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.</p><p>The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/841b456b86547fecd4464e1358e26c20\" tg-width=\"1298\" tg-height=\"684\" width=\"100%\" height=\"auto\"/><span>A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNAL</span></p><p>Moderna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.</p><p>Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.</p><p>Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.</p><p>This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.</p><p>The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b3380b351f910af68ef191b100997c93\" tg-width=\"957\" tg-height=\"615\" width=\"100%\" height=\"auto\"/><span>Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWS</span></p><p>A second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.</p><p>Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.</p><p>As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.</p><p>Moderna didn’t respond to a request for comment regarding the patent.</p><p>Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.</p><p>In October 2020, a small San Diego company, Allele Biotechnology &amp; Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.</p><p>Pfizer and BioNTech dispute the claim, and the litigation is pending.</p><p>Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.</p><p>Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.</p><p>A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.</p><p>More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.</p><p>That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.</p><p>A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Invented Covid-19 Vaccines? Drugmakers Battle Over Patents\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented ...</p>\n\n<a href=\"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","BNTX":"BioNTech SE"},"source_url":"https://www.wsj.com/articles/who-invented-covid-vaccines-11640726776?mod=business_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1143463942","content_text":"A high-stakes legal battle is taking shape over lucrative patent rights for Covid-19 vaccines, with drug companies pitted against each other and government and academic scientists over who invented what.The U.S. government andModernaInc., whose collaboration led to one of the most widely used shots, have fought over who discovered a key component and owns its rights. Meantime,PfizerInc. and BioNTech SE, makers of another leading vaccine, are in a patent battle with a smaller company, and some analysts think they could end up facing off against Moderna.At the heart of the disputes: Who can claim to have invented important elements of the Covid-19 vaccines?Hundreds of millions of dollars are at stake. If anyone succeeds in establishing a role in the discovery of the vaccines, Pfizer and Moderna would have to share with others a bigger cut of the tens of billions of dollars in vaccine sales being generated.“It’s scientific credit and money. That’s what people want,” said Jacob Sherkow, a professor who specializes in biotechnology intellectual property at the University of Illinois College of Law. “This is a major biotech invention, for which tens of billions of dollars are riding on the line.”The market for Covid-19 vaccines has proven to be bigger than initially expected.PHOTO:AMIR HAMJA FOR THE WALL STREET JOURNALThe emerging patent disputes cast a shadow over what has otherwise been a remarkable scientific, government and business accomplishment: the development of several effective Covid-19 vaccines at unprecedented speed, during a pandemic.Who deserves credit for medical discoveries has long been a battleground for companies, academia and government. Patents are especially valuable in the pharmaceutical industry because they can give a company the exclusive right to sell a drug or vaccine for many years, free from generic competition.They can also be valuable to scientists—and the universities and government labs they work for—if a drug company licenses a patent and pays royalties on sales. Princeton University built a $278 million chemistry lab using royalties from sales ofEli Lilly& Co.’s cancer drug Alimta, based on research by a university professor.Yet the disputes can be hard to sort out because they involve who gets credit for complicated research that often builds upon a series of iterative discoveries.Multi-company patent battles have erupted in the past over lucrative new drug markets, such as treatments for hepatitis C in the mid-2010s.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere.PHOTO:PFIZER/ASSOCIATED PRESSThe market for Covid-19 vaccines has proven to be bigger than Wall Street initially expected. Pfizer and Moderna have booked a combined $35 billion in Covid-19 vaccine sales globally for the first nine months of 2021.Analysts estimate the two vaccines will post combined sales of more than $52 billion in 2022, helped by demand for booster shots.Pfizer, BioNTech and Moderna already pay royalties on sales of their vaccines because they rely in part on research conducted elsewhere. Both BioNTech and Moderna previously licensed patents on messenger RNA research conducted by scientists at the University of Pennsylvania, and BioNTech has licensed a patent from the federal government, for which Pfizer has a sub-license. Moderna paid out $400 million in royalties, including to companies that hold the rights to the Penn patents, on sales of its Covid-19 vaccine for the first nine months of 2021.One dispute stems from Moderna’s decision to deny a National Institutes of Health request to list government scientists as co-inventors on the company’s application for a U.S. patent covering a key component of its Covid-19 vaccine.The patent would have claimed the invention of a genetic sequence incorporated into the Moderna vaccine to trigger an immune response against the coronavirus. The dispute was earlier reported by the New York Times.A lab inside a Moderna facility. The company says only its scientists came up with the messenger RNA sequence for its Covid-19 vaccine.PHOTO:MADDIE MALHOTRA FOR THE WALL STREET JOURNALModerna was working with the NIH on vaccine research for a few years before the novel coronavirus emerged, and they collaborated in developing and testing the Covid-19 vaccine soon after the pandemic began.Moderna said it has credited government scientists on other patent applications related to its vaccine, such as one covering dosing, but government scientists didn’t help invent the genetic sequence used in the vaccine.Moderna said only its scientists came up with the messenger RNA sequence, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and triggers the immune response.This month,Moderna dropped the patent application, saying it wanted to allow more time for discussions with the NIH aimed at an amicable resolution.The NIH said it welcomed the opportunity to work with the company to resolve patent issues in a way that recognizes the contribution of NIH scientists.Both Pfizer-BioNTech and Moderna’s mRNA vaccines use versions of the genetic sequence of the coronavirus spike protein.PHOTO:CYRIL MARCILHACY/BLOOMBERG NEWSA second dispute could emerge over an NIH patent for an engineered version of the coronavirus spike protein. The engineered spike protein helps a vaccine induce a stronger immune response. Versions of the genetic sequence of the spike protein are found in mRNA vaccines, including Moderna’s and Pfizer’s.Vaccine makers, including Pfizer and partner BioNTech, obtained a license to the NIH patent, but Moderna hasn’t.As long as Moderna doesn’t have a license, its vaccine infringes upon the NIH patent, according to Christopher Morten, associate clinical professor of law at Columbia Law School who researches biotech and other patents. He has estimated Moderna could be on the hook to pay more than $1 billion to the government for infringing the patent.Moderna didn’t respond to a request for comment regarding the patent.Both Pfizer and Moderna already are engaged in patent battles with other companies in connection with their vaccines.In October 2020, a small San Diego company, Allele Biotechnology & Pharmaceuticals, sued Pfizer and BioNTech, saying the companies were using a protein in their vaccine testing that infringed on an Allele patent.Pfizer and BioNTech dispute the claim, and the litigation is pending.Before the pandemic, Moderna initiated a U.S. patent-office proceeding to invalidate patents held by Arbutus BiopharmaCorp.Those claim the invention of certain nanoparticles, like the kind found in Moderna’s Covid-19 vaccine, which help deliver a vaccine’s RNA inside human cells.Moderna said it uses its own proprietary nanoparticles, which aren’t covered by the claims in the Arbutus patents.A Moderna loss could ultimately cause the company to pay royalties to Arbutus, according to some analysts. A U.S. appeals court on Dec. 1 upheld some of the Arbutus patent claims. Arbutus and a partner company that licensed the patents said they are pleased with the court’s decision.More patent lawsuits could arise. Last year, Moderna said it wouldn’t enforce patents related to its Covid-19 vaccine while the pandemic emergency continued, but would seek to license its patents to other companies once the pandemic emergency is over.That prospect has left open the possibility that Moderna could file patent-infringement lawsuits against other companies, including Pfizer and BioNTech, if they don’t agree on license terms, according to some patent experts and Wall Street analysts.A Pfizer spokeswoman said the company doesn’t expect intellectual property to be a barrier to the availability of its vaccine. The company expects that any desired third-party licenses would be available on reasonable terms.","news_type":1},"isVote":1,"tweetType":1,"viewCount":129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9003327935,"gmtCreate":1640884649383,"gmtModify":1676533551118,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Superb","listText":"Superb","text":"Superb","images":[{"img":"https://static.itradeup.com/news/04bd5d6fab6a75ca6b03b059bbdf6566","width":"1344","height":"2139"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9003327935","isVote":1,"tweetType":1,"viewCount":136,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9009823704,"gmtCreate":1640616470570,"gmtModify":1676533529449,"author":{"id":"4095642275585470","authorId":"4095642275585470","name":"GolDBeaR","avatar":"https://static.tigerbbs.com/350a4a38140f5c611fddf649b5c0208c","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095642275585470","idStr":"4095642275585470"},"themes":[],"htmlText":"Up up","listText":"Up up","text":"Up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009823704","repostId":"9009820967","repostType":1,"repost":{"id":9009820967,"gmtCreate":1640616177720,"gmtModify":1676533529377,"author":{"id":"3576159031156193","authorId":"3576159031156193","name":"4ZOEYS","avatar":"https://static.tigerbbs.com/485a6405c364ce85c22e81b2913d390f","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3576159031156193","idStr":"3576159031156193"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","listText":"<a href=\"https://ttm.financial/S/TIGR\">$Tiger Brokers(TIGR)$</a>Moved a little too fast,","text":"$Tiger Brokers(TIGR)$Moved a little too fast,","images":[{"img":"https://static.itradeup.com/news/c56f3695dae52d48a6c8a24c1ca8e88d","width":"1125","height":"3766"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9009820967","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}